OSMOLEX ER

Peak

amantadine hydrochloride

Supernus Pharmaceuticals

NDAORALTABLET, EXTENDED RELEASE

Approved

Feb 2018

Lifecycle

Peak

Competitive Pressure

0/100

Loss of Exclusivity

LOE Date

Feb 15, 2038

145 months away

Patent Expiry

Feb 15, 2038

Patent Records (5)

Patent #	Expiry	Type	Use Code
8389578	Jan 22, 2028		U-219
8252331	Mar 13, 2030	Product	—
10500170	Feb 15, 2038		U-20
10500171	Feb 15, 2038		U-2497
10213393	Feb 15, 2038		U-20

Company

Supernus Pharmaceuticals

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers